RAJAF TFA Therapeutics, Inc.
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1885680 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-0.6%
TTM net income YoY31.6%
TTM EPS YoY—
Revenue 3-yr CAGR185.9%
Net income 3-yr CAGR—
Margins
Gross margin61.1%
Operating margin-11.3%
Net margin-12.4%
FCF margin—
EBITDA margin-0.5%
Returns
ROE—
ROA-3.3%
ROIC (approx.)—
Asset turnover0.27x
Leverage & solvency
Liabilities / assets111.5%
Debt / equity—
Current ratio0.19x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.23x
Accruals ratio-2.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.25M | $1.25M |
| Cost of revenue | $484,607 | $347,004 |
| Gross profit | $760,741 | $906,480 |
| Operating income | -$141,128 | -$183,913 |
| Pretax income | -$154,822 | -$191,301 |
| Income tax | — | $34,957 |
| Net income | -$154,822 | -$226,258 |
| EBITDA | -$5,885 | $223,352 |
| EPS (basic) | 0.00 | 0.00 |
| EPS (diluted) | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 111.12M | 111.12M |
| Balance sheet | ||
| Cash & equivalents | $3,199 | $37,284 |
| Receivables | — | $305 |
| Inventory | $674,196 | — |
| Current assets | $997,742 | $601,602 |
| PP&E, net | $3.63M | $3.91M |
| Total assets | $4.66M | $4.62M |
| Current liabilities | $5.19M | $4.99M |
| Total liabilities | $5.19M | $5.00M |
| Shareholders' equity | -$534,551 | -$375,543 |
| Shares outstanding | 111.12M | 111.12M |
| Cash flow statement | ||
| Operating cash flow | -$35,845 | $312,006 |
| Capital expenditure | — | $349,237 |
| Free cash flow | — | -$37,231 |
| Investing cash flow | — | -$305,637 |
| Depreciation & amortization | $135,243 | $407,265 |
Free plan shows the latest 2 periods; Pro shows all 5 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.